New Delhi (CNN) Indian pharmaceutical company Bharat Biotech announced on the 3rd that the new coronavirus vaccine “Covaxin” developed by the company has an effective rate of 93.4% or more for prevention of aggravation and 77 for prevention of onset. It was revealed that it was 8.8%. The company said in a statement that it had completed the final analysis of a phase 3 clinical trial (clinical trial). He said it would be the largest corona vaccine clinical trial in India. 25,800 people aged 18-98 participated in the trial. Of these, 2433 were over 60 years old and 4,500 had comorbidity. The protective effect against the first mutant strain (Delta strain) found in India was 65.2%. The Delta strain is currently the dominant mutant strain in India. The data was published on the site “MedRxiv” where pre-reviewed papers can be published. Krishna Ella, chairman of Bharat Biotech, said the results of the trial “established the ability to focus on innovation in India and developing countries.” Double-dose covaxin was approved for limited emergency use in India in January, before the provisional results of the Phase 3 clinical trial were available. According to the company, emergency use authorizations have been granted in 16 countries, including Brazil, the Philippines, Iran and Mexico.